摘要
目的:探讨二甲双胍治疗老年2型糖尿病的临床疗效和安全性。方法:选取2016.02—2017.02来我院就诊的110例老年2型糖尿病患者为研究对象,根据治疗方案的不同,随机分为观察组和对照组,每组55例。其中,观察组给予二甲双胍进行治疗,对照组给予格列喹酮进行治疗,疗程均为12周,比较两组患者的空腹血糖、餐后2小时血糖、糖化血红蛋白水平,临床有效率,以及肝、肾等功能情况。结果:治疗前,两组患者的空腹血糖、餐后2h血糖、糖化血红蛋白水平无显著差异,P>0.05;治疗后,两组患者的空腹血糖、餐后2h血糖、糖化血红蛋白水平均下降,且观察组的下降程度比对照组更显著,差异有统计学意义,P<0.05;治疗后,观察组的临床有效率为94.55%,显著高于对照组的72.73%,差异有统计学意义,P<0.05;治疗前、后两组患者的肝、肾功能相关指标均无显著差异,P>0.05。结论:二甲双胍能有效降低老年2型糖尿病患者的血糖水平,临床疗效显著,且对肝、肾功能影响较小,安全性高,值得临床推广应用。
Objective:To investigate the clinical efficacy and safety of metformin in elderly patients with type 2 diabetes.Methods:110 elderly patients with type 2 diabetes who came to our hospital from 2016.02 to 2017.02 were selected as study subjects.According to the treatment plan,they were randomly divided into observation group and control group,with 55 cases in each group.Among them,the observation group was treated with metformin,and the control group was treated with gliquidone,and the course of treatment in both groups was 12 weeks.The fasting blood glucose,postprandial blood glucose,HbA1c levels,clinical efficiency,and liver and kidney function were compared between the two groups.Results:There was no significant difference in fasting blood glucose,postprandial 2h blood glucose,and glycated hemoglobin levels between the two groups before treatment(P>0.05).After treatment,fasting blood glucose,postprandial blood glucose,and HbA1c were decreased in the two groups,and the degree of decline in the observation group was more significant than that in the control group(P<0.05).After treatment,the clinical effective rate was 94.55%in the observation group,which was significantly higher than 72.73%in the control group(P<0.05).There was no significant difference in the liver and kidney function indicators between the two groups before and after treatment(P>0.05).Conclusion:Metformin can effectively reduce the blood glucose level in elderly patients with type 2 diabetes.The clinical curative effect is significant,and the effect on liver and renal function is small,and the safety is high.It is worthy of clinical application.
作者
张京伟
ZHANG Jing-wei(Majiapu Community Health Service Center,Beijing 100071,China)
出处
《药品评价》
CAS
2018年第14期48-50,54,共4页
Drug Evaluation